Hm Payson & CO Cassava Sciences Inc Transaction History
Hm Payson & CO
- $5.81 Billion
- Q3 2024
A detailed history of Hm Payson & CO transactions in Cassava Sciences Inc stock. As of the latest transaction made, Hm Payson & CO holds 50 shares of SAVA stock, worth $126. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50
Previous 50
-0.0%
Holding current value
$126
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding SAVA
# of Institutions
196Shares Held
13.8MCall Options Held
2.98MPut Options Held
6.57M-
Black Rock Inc. New York, NY3.22MShares$8.15 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.52MShares$6.38 Million0.0% of portfolio
-
State Street Corp Boston, MA1.16MShares$2.94 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.01MShares$2.55 Million0.0% of portfolio
-
Gallacher Capital Management LLC Lone Tree, CO580KShares$1.47 Million7.83% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $101M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...